PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Helixmith has secured a royalty-generating foothold after its Chinese partner won approval for an Engensis-based therapy, even as quarterly losses have widened again in 2026.
Chinese partner Northland Biotech won NMPA approval for its Engensis(VM202)-based gene therapy 'NL003,' securing a seven-year royalty structure after commercialization.
2025 consolidated revenue was KRW 2.6 billion with an operating loss of KRW 9.9 billion, both narrower than 2022-2024, while the owners' net loss shrank to KRW 0.43 billion.
However, owners' net losses widened again to KRW 1.4 billion in Q1 2026 and KRW 2.06 billion in Q2 2026, breaking the 2025 trend of narrowing losses.
Under majority shareholder Biosolution, which took control in late 2023, Helixmith has cut headcount, restructured its pipeline, and is co-developing a CAR-T pipeline with Biosolution.
Helixmith is pursuing global business-development talks for Engensis after attending BIO International Convention 2026 for the first time in five years.
Helixmith is a gene and cell therapy developer whose core asset is the gene therapy 'Engensis (VM202).' Engensis works by injecting a DNA plasmid expressing hepatocyte growth factor (HGF) into muscle to induce angiogenesis and nerve regeneration; it was originally developed for diabetic peripheral neuropathy (DPN) in the United States but failed to meet its primary endpoint in a Phase 3 trial.
Development subsequently shifted toward critical limb ischemia (CLI), with Chinese partner Northland Biotech, which licensed the technology in 2004, independently running Phase 1 through 3 trials locally.
In May 2026, Northland Biotech obtained approval from China's National Medical Products Administration (NMPA) for its Engensis-based therapy 'NL003.' Under the agreement, Helixmith is entitled to royalties equal to the greater of seven percent of net sales or four percent of gross sales for seven years after commercialization.
Beyond Engensis, the company selectively continues research on AAV gene therapy and antibody candidates based on development progress and market potential, and it holds chimeric antigen receptor (CAR)-based core technology that underpins a CAR-T pipeline co-developed with majority shareholder Biosolution.
Control changed hands in December 2023 through a management transfer agreement and third-party share issuance to Biosolution, a company with cell therapy commercialization experience via products such as CartiLife and Keraheal, and Biosolution's stake has since expanded through additional purchases.
Helixmith maintains its own GMP manufacturing infrastructure at its Magok R&D center and has also joined a government-backed R&D project for smart manufacturing processes for cell and gene therapies. Revenue scale itself remains small, and no segment-level revenue breakdown has been separately confirmed in disclosures.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩600M | -₩2B | −324.8% |
| 2025Q3 | ₩600M | -₩2.7B | −474.0% |
| 2025Q4 | ₩500M | -₩2.4B | −484.2% |
| 2026Q1 | ₩600M | -₩2.2B | −395.9% |
| 2026Q2 | ₩800M | -₩2.2B | −269.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩2.8B | -₩52.6B | -₩43.5B | −1878.1% | −20.1% | 17.4% |
| 2023 | ₩4.2B | -₩35.2B | -₩64.1B | −838.9% | −41.6% | 47.9% |
| 2024 | ₩5B | -₩18B | -₩15.5B | −361.0% | −10.9% | 4.8% |
| 2025 | ₩2.6B | -₩9.9B | -₩400M | −381.0% | −0.3% | 1.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
2025 consolidated revenue was KRW 2.6 billion (2,598,149,668 won), roughly half of 2024's KRW 5.0 billion, while the operating loss narrowed to KRW 9.9 billion from KRW 18.0 billion in 2024, KRW 35.2 billion in 2023, and KRW 52.6 billion in 2022.
The owners' net loss widened to KRW 43.5 billion in 2022 and KRW 64.1 billion in 2023 before sharply narrowing to KRW 15.5 billion in 2024 and KRW 0.43 billion in 2025, a trend attributable to reduced selling and administrative expenses alongside non-operating gains from financial asset management.
Because revenue remains small, the operating margin stayed deeply negative, moving from -1,878.1% in 2022 to -381.0% in 2025. The debt ratio fell sharply from 47.9% in 2023 to 4.8% in 2024 and 1.2% in 2025, indicating minimal financial leverage.
On a quarterly basis, Q2 2025 revenue was KRW 0.61 billion with an operating loss of KRW 2.0 billion and an owners' net loss of KRW 0.76 billion, before losses widened somewhat in Q3 2025 to a KRW 0.56 billion revenue, KRW 2.7 billion operating loss, and KRW 1.0 billion net loss.
In Q4 2025, despite revenue falling to KRW 0.49 billion and an operating loss of KRW 2.4 billion, the owners' net result swung to a KRW 2.87 billion profit, apparently reflecting a one-off non-operating item likely tied to financial asset valuation gains.
However, losses widened again in 2026, with an owners' net loss of KRW 1.4 billion in Q1 and KRW 2.06 billion in Q2 despite revenue rising to KRW 0.81 billion, bringing the trailing four-quarter (Q3 2025 through Q2 2026) owners' net loss total to roughly KRW 1.6 billion.
Critical limb ischemia (CLI), the target indication for Engensis, is a severe disease in which impaired blood flow in the legs leads to ulceration and tissue necrosis; Northland Biotech estimates more than six million CLI patients in China alone, and the global CLI treatment market is valued in the trillions of won.
Gene-therapy-based vascular regeneration is drawing attention as a new treatment axis relative to existing drugs and procedures, but with few commercialized precedents, this China approval is viewed within the industry as a notable case.
In Korea's cell and gene therapy (CGT) sector, multiple companies are competitively expanding pipelines including CAR-T, with HLB Group's Verismo Therapeutics advancing clinical trials of its KIR-CAR platform for solid tumors, diversifying the competitive landscape in CAR-T.
Helixmith, which holds CAR-based core technology, has a foothold in this trend but remains at an early clinical stage relative to competitors.
Analysts note that Northland Biotech's commercialization experience and sales data in China could serve as reference material for future partnership discussions in major markets such as the United States and Europe.
However, gene therapies are subject to industry dynamics where regulatory review standards and price/reimbursement negotiations in each country determine commercial success, meaning meaningful revenue scale-up can take time even after approval.
In June 2026, the company attended the BIO International Convention (BIO USA) 2026 in San Diego for the first time in five years, launching in-depth global business-development discussions for Engensis.
The company said meeting requests from global biotech firms increased following Northland Biotech's China approval, and it plans to pursue local co-development, investment, and technology-licensing discussions across the United States, Europe, and the Middle East.
In the United States, Helixmith previously completed a Phase 2 trial for critical limb ischemia and says it received positive feedback from the U.S. Food and Drug Administration in a 2025 Type D meeting regarding primary endpoint design for a potential Phase 3 trial.
In China, once Northland Biotech begins commercializing NL003, contractual royalty payments are scheduled to follow, representing a window for potential financial benefit to flow into future results.
Separately, in June 2026 Helixmith was selected for a Ministry of Trade, Industry and Energy biohealth R&D program, receiving KRW 4.75 billion in government funding within a KRW 6.54 billion consortium project to build smart manufacturing processes for cell and gene therapies.
Its CAR-T pipeline continues to be co-developed with majority shareholder Biosolution in pursuit of business synergies.
However, most of these business-development, licensing, and clinical-restart items remain at the discussion or review stage, and the timing of concrete contracts or revenue recognition has not been confirmed.
The company has posted net losses for several consecutive years and generates limited revenue, keeping it in a range where traditional earnings-based valuation metrics are difficult to apply meaningfully.
That said, the owners' net loss narrowed directionally and substantially between 2022 and 2025, and the debt ratio has also fallen sharply, easing balance-sheet-related pressure.
The shares tend to trade at levels not far removed from net asset value, without a clearly observable large premium or discount relative to net assets. The company does not pay dividends, so shareholder-return appeal through dividends is limited.
With the new development of a China product approval, whether royalty income materializes and the direction of quarterly earnings remain factors that could continue to influence how the market assesses the company going forward.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Northland Biotech received NMPA approval for NL003, giving Helixmith a royalty structure equal to the greater of 7% of net sales or 4% of gross sales for seven years after commercialization. The review priority rank reportedly moved quickly from seventh in December 2025 to second by early 2026 before approval followed. As commercialization proceeds, there is room for new financial contributions to appear in future results.
The debt ratio fell from 47.9% in 2023 to 1.2% in 2025, alongside continued cuts in selling and administrative expenses. The owners' net loss also narrowed sharply from KRW 64.1 billion in 2023 to KRW 0.43 billion in 2025.
That said, this trend reversed and widened again in the first half of 2026, which should be weighed alongside the improvement.
Helixmith is co-developing a CAR-T pipeline with majority shareholder Biosolution, drawing on the latter's cell therapy commercialization experience.
In June 2026, it was selected for a Ministry of Trade, Industry and Energy biohealth R&D program, securing KRW 4.75 billion in government funding within a KRW 6.54 billion consortium to advance smart manufacturing processes for cell and gene therapies.
After a temporary owners' net profit of KRW 2.87 billion in Q4 2025, the company returned to net losses of KRW 1.4 billion and KRW 2.06 billion in Q1 and Q2 2026, respectively. Revenue rose to KRW 0.81 billion in Q2 2026 but remains insufficient to offset the loss scale.
2025 consolidated revenue fell to KRW 2.6 billion, roughly half of the KRW 5.0 billion recorded in 2024. Most revenue appears to stem from small-scale sources rather than large commercial sales, and no segment-level revenue breakdown has been separately confirmed.
Engensis previously failed to meet its primary endpoint in a U.S. Phase 3 trial for diabetic peripheral neuropathy. While attendance at BIO USA 2026 initiated global partnering discussions, no concrete contract or timeline has been confirmed, and talks remain at an early stage.
Whether Helixmith will restart a U.S. Phase 3 trial for Engensis remains unconfirmed, and the drug previously failed to meet its primary endpoint in the diabetic peripheral neuropathy indication.
Even with a renewed attempt in critical limb ischemia, timelines could be delayed depending on regulatory review and further clinical results.
With a small revenue base, most R&D spending relies on internal cash and gains from financial asset management, and given that net losses widened again in the first half of 2026, the sustainability of any future earnings improvement remains uncertain. The operating margin still sits deep in negative territory.
Majority shareholder Biosolution accounts for Helixmith as an equity-method affiliate, meaning fluctuations in Helixmith's earnings feed into Biosolution's own results. This is a structural factor that could affect the parent's capacity or strategic decisions regarding further support.
Timing of the Q3 2026 quarterly report, which will show whether the net-loss widening seen in the first half of 2026 continues.
Whether the global partnering and licensing discussions launched at BIO USA 2026 progress into concrete agreements, and whether any announcements emerge regarding the U.S. or European markets.
Confirmation of when Northland Biotech actually begins sales of NL003 and the resulting timing and scale of royalty payments to Helixmith.
Whether progress updates or outcomes are announced for the smart manufacturing process consortium project selected in June 2026.
Since Biosolution became majority shareholder in late 2023, Helixmith has cut headcount, restructured its pipeline, and reduced selling and administrative expenses, sharply narrowing the owners' net loss from KRW 64.1 billion in 2023 to KRW 0.43 billion in 2025.
Chinese partner Northland Biotech's NMPA approval for an Engensis-based therapy also created a new royalty structure that could generate income over the next seven years. However, owners' net losses widened again to KRW 1.4 billion in Q1 2026 and KRW 2.06 billion in Q2 2026, breaking from the 2025 narrowing trend.
Revenue itself remains small, falling to KRW 2.6 billion in 2025 from 2024 levels, indicating a still-thin commercial revenue base. Global partnering discussions launched at BIO USA 2026 remain at an early stage without confirmed contracts or timelines, and the prior U.S. Phase 3 failure is also worth weighing.
While a very low debt ratio limits financial strain, the earnings base remains fragile, making future quarterly profit-and-loss trends and the actual realization of Chinese royalty income key points to watch.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.